

Connetics Corporation

[View the current Connetics Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/2944-Connetics+Corporation.html)

(<http://www.bioportfolio.com/biocorporate/2944-Connetics+Corporation.html>)

Contact Details:

3290 West Bayshore Road
Palo Alto
CA
94303
United States of America

Tel: 650 843 2800
Fax: 650 843 2899
Email:

Connetics Corporation is focused on the acquisition, development and commercialization of marketed and late-stage products. The Company's product and commercial focus is initially targeted at rheumatology and dermatology, two specialty medical markets. These commercially attractive markets have large patient populations yet relatively small physician treating groups. U.S. dermatologists and rheumatologists write prescriptions each year exceeding \$5.0 billion. The Company's goal is to leverage these markets by commercializing novel products to meet currently unmet medical needs

and employing focused and highly trained sales staff. Connetics currently markets Ridaura(R) (auranofin), a treatment for rheumatoid arthritis, and ACTIMMUNE(R) (interferon gamma-1b), a treatment for chronic granulomatous disease (beginning January 1999). On March 1, 1999 Connetics received clearance from the FDA to begin marketing Luxiq(TM) (betamethasone valerate) Foam, 0.12%, a product to treat corticosteroid-responsive scalp dermatoses. Connetics has several other products in development: ConXn(R) (recombinant human relaxin H2) ("relaxin"), targeting scleroderma, organ fibrosis, and infertility; and OLUX(TM) (clobetasol propionate) Foam, 0.05%, a novel formulation for the treatment of severe scalp dermatoses; and interferon gamma (through its wholly-owned subsidiary, InterMune Pharmaceuticals, Inc.) for the treatment of certain congenital, infectious and other diseases.

Recent Publications by Connetics Corporation:



- [A novel foam vehicle for delivery of topical corticosteroids.](#)
Skin, particularly the uppermost layer--the stratum corneum--presents a... 11th November, 2005
Center for Skin Biology, Connetics Corp, Palo Alto, California 94303, USA.- J Am Acad Dermatol. 2005 Jul;53(1 Suppl 1):S26-38. ([DOI Direct Link](#))
- [Simultaneous determination of tretinoin and clindamycin phosphate and their degradation products in](#)

[topical formulations by reverse phase HPLC.](#)

*A new HPLC method based on reverse phase separation and photodiode-array...*9th October, 2004
Connetics Australia Pty. Ltd, 8 Macro Crt, Rowville, VIC 3178, Australia.- J Sep Sci. 2004
Jan;27(1-2):71-7.

• [Bioavailability of clobetasol propionate in different vehicles.](#)

*Topical clobetasol propionate is widely used for the treatment of...*11th October, 2003
Connetics Corporation, Palo Alto, Calif., USA.- Skin Pharmacol Appl Skin Physiol. 2003
Jul-Aug;16(4):212-6. ([DOI Direct Link](#))

• [Relaxin activates the MAP kinase pathway in human endometrial stromal cells.](#)

*The reproductive hormone, relaxin, is structurally similar to insulin and...*26th November, 2002
Connetics Corporation, 3400 West Bayshore Rd., Palo Alto, California- J Cell Biochem.
2002;85(3):536-44. ([DOI Direct Link](#))

• [Systemic administration of recombinant human relaxin \(RHRLX\) ameliorates the acute cyclosporine nephrotoxicity in rats.](#)

*The reproductive hormone, relaxin, is structurally similar to insulin and...*16th March, 2001
Connetics Corporation, Palo Alto, CA, USA- J Heart Lung Transplant. 2001 Feb;20(2):253.

• [Transcriptional inhibition of stromelysin by interferon-gamma in normal human fibroblasts is mediated by the AP-1 domain.](#)

*The expression of the major matrix-degrading metalloproteinase,...*20th June, 2000
Connetics Corporation, Palo Alto, California 94303, USA.- J Cell Biochem. 1999 Mar 1;72(3):373-86.

Press Releases on Connetics Corporation:

Centene Corporation to Present at Bank of America Merrill Lynch Credit Conference	20th November, 2009	Centene Corporation	<i>ST. LOUIS, Nov. 20 /PRNewswire-FirstCall/ -- Centene Corporation (NYSE: CNC) today announced that it will present at the Bank of America Merrill Lynch 2009 Credit Conference, to be held December 2-3,</i>
Reportlinker Adds Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015	20th November, 2009	Reportlinker	<i>NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide,</i>
Reportlinker Adds Medical Adhesives and Sealants - A US Market Review	20th November, 2009	Reportlinker	<i>NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Medical Adhesives and Sealants - A US Market Review http://www</i>
Reportlinker Adds Toothpaste - Global Market Trends	20th November, 2009	Reportlinker	<i>NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Toothpaste - Global Market Trends http://www.reportlinker.com/p0164389</i>

[Reportlinker Adds
Global Self
Monitoring Blood
Glucose Market
\(SMBG\): Increasing
Adoption to Drive
Growth](#)

20th November,
2009 Reportlinker

NEW YORK, Nov. 20 /PRNewswire/ --
Reportlinker.com announces that a new
market research report is available in its
catalogue. Global Self Monitoring Blood
Glucose Market (SMBG): Increasing Adoption
to

Connetics Corporation Clinical Trials:



- [Acitretin and Etanercept in Psoriasis](#)

Connetics Corporation Patents:



- 7222754- [Aerosol system having lockable cap](#)
- 5776459- [TCR V beta 5 peptides](#)
- 5811395- [Relaxin analogs and derivatives methods and uses thereof](#)
- 5911997- [Relaxin-like factor and methods and uses thereof](#)
- 6200953- [Relaxin analogs and derivatives compositions](#)
- 6211147- [Method of promoting angiogenesis using relaxin](#)
- 6730288- [Mousse composition](#)
- 6946120- [Pharmaceutical composition](#)
- 7029659- [Mousse composition](#)
- 7070069- [Aerosol system having lockable cap](#)
- 7078058- [Corticosteroid-containing pharmaceutical composition](#)
- 7118734- [Non-aqueous liquid shampoo composition](#)
- 7141237- [Pharmaceutical foam](#)
- 5753623- [Method of treatment for depression](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core

information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

